-Biswadeep Sen, Amity University Kolkata
We all can agree to the fact that despite the advancement in the treatments and technology, Lung Cancer is still, by far, the leading cause of cancer death worldwide. Amongst the multiple oncogenic driver alterations discovered the one with the most frequent aberration is KRAS mutation. To make matters worse, no effective therapies are formulated to date.
Now, this study shows the demonstration of a positive prognostic factor, miR-34c-3p having an impact on the KRAS mutated patients suffering from NSCLC. While the in-vitro assays revealed that the microRNA overexpression does make the chances of apoptosis very likely, the computational analysis unearthed the fact that CDK1, a target that is known for its involvement in KRASmut cells, is a target of miR-34c-3p.
Hence together with the CDK1inhibition and the MicroRNA overexpression, we might be able to bring down the proliferation rate of cancer, allowing tailored treatment for the patients suffering from NSCLC via KRAS mutation.
Citation:
Palma F, Affinito A, Nuzzo S, et al.; miR-34c-3p targets CDK1 a synthetic lethality partner of KRAS in non-small cell lung cancer [published online ahead of print, 2020 Sep 18]. Cancer Gene Therapy 2020; DOI:10.1038/s41417-020-00224-1
Find more articles in https://bioxone.in//
FELUDA – the rapid test strip method to detect COVID-19
-Ruchita Karmakar, Amity University Kolkata A research team led by Debojyoti Chakraborty and Souvik Maiti of CSIR and TATA group came up with a new test named FELUDA to detect COVID-19. It’s a paper test strip that gives a precise result within 30 minutes; Approved for commercial launch by the Drugs Controller General of India. […]